ES2051738T3 - Derivados aminicos de compuestos analogos a acido folico. - Google Patents

Derivados aminicos de compuestos analogos a acido folico.

Info

Publication number
ES2051738T3
ES2051738T3 ES87304093T ES87304093T ES2051738T3 ES 2051738 T3 ES2051738 T3 ES 2051738T3 ES 87304093 T ES87304093 T ES 87304093T ES 87304093 T ES87304093 T ES 87304093T ES 2051738 T3 ES2051738 T3 ES 2051738T3
Authority
ES
Spain
Prior art keywords
conjugates
folic acid
antibody
vivo
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87304093T
Other languages
English (en)
Inventor
Daniel J Coughlin
Anthony Dwight Lopes
Robert D Radcliffe
John D Rodwell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytogen Corp
Original Assignee
Cytogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytogen Corp filed Critical Cytogen Corp
Application granted granted Critical
Publication of ES2051738T3 publication Critical patent/ES2051738T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

SE PRESENTAN NUEVOS CONJUGADOS DE ANTICUERPOS TERAPEUTICOS QUE COMPRENDEN DERIVADOS AMINOS DE ACIDO FOLICO ENLAZADOS COVALENTEMENTE POR MEDIO DE UN GRUPO AMINO REACTIVO A UNA MOLECULA DE CARBOHIDRATO OXIDADA DE UN ANTICUERPO O FRAGMENTO DE ANTICUERPO. LOS COJUNGADOS RETIENEN SUSTANCIALMENTE LA MISMA INMUNOESPECIFICIVIDAD E INMUNOREACTIVIDAD DE LA MOLECULA DE ANTICUERPO NO CONJUGADO. LA INMUNOESPECIFICIVIDAD Y LA INMUNOREACTIVIDAD DE LOS CONJUGADOS DEL ANTICUERPO PERMITEN LA LIBERACION DEL DERIVADO AMINO ENLAZADO TERAPEUTICAMENTE EFECTIVO DEL ACIDO FOLICO IN VIVO. LOS CONJUGADOS SON TERAPEUTICAMENTE EFECTIVOS CONTRA UNA VARIEDAD DE DESORDENES CELULARES NEOPLASTICOS Y NO NEOPLASTICOS CUANDO SE ADMINISTRA IN VIVO. TAMBIEN SE HAN DESCUBIERTO METODOS PARA LA SINTETIZACION DE LOS DERIVADOS AMINO DEL ACIDO FOLICO, METODOS PARA LA PREPARACION DE CONJUGADOS DE ANTICUERPO Y METODOS PARA EL USO DE LOS CONJUGADOS IN VIVO.
ES87304093T 1986-05-08 1987-05-07 Derivados aminicos de compuestos analogos a acido folico. Expired - Lifetime ES2051738T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86103786A 1986-05-08 1986-05-08

Publications (1)

Publication Number Publication Date
ES2051738T3 true ES2051738T3 (es) 1994-07-01

Family

ID=25334695

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87304093T Expired - Lifetime ES2051738T3 (es) 1986-05-08 1987-05-07 Derivados aminicos de compuestos analogos a acido folico.

Country Status (11)

Country Link
EP (1) EP0251455B1 (es)
JP (1) JP2564586B2 (es)
AT (1) ATE105484T1 (es)
AU (1) AU7359087A (es)
CA (1) CA1330378C (es)
DE (1) DE3789788T2 (es)
DK (1) DK5188A (es)
ES (1) ES2051738T3 (es)
FI (1) FI880059A7 (es)
WO (1) WO1987006837A1 (es)
ZA (1) ZA873305B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK8189A (da) * 1988-01-12 1989-07-13 Bunge Australia Antigen-antistof-konjugater, deres fremstilling og anvendelse
US5028697A (en) * 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5144012A (en) * 1988-08-08 1992-09-01 Eli Lilly And Company Cytotoxic drug conjugates
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
DE68924783T2 (de) * 1988-09-30 1996-03-28 Neorx Corp Wässrige additivsysteme, verfahren und polymerteilchen.
JPH04504713A (ja) * 1988-11-18 1992-08-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 共役ポリペプチドとその調製および使用方法
US5157123A (en) * 1989-03-13 1992-10-20 Georgetown University S-(2-thiopyridyl)-l-cysteine, a heterobifunctional crosslinking reagent
US5208008A (en) * 1990-11-14 1993-05-04 University Of Pittsburgh Regioselective chemical modification of monoclonal antibodies
US5547668A (en) * 1995-05-05 1996-08-20 The Board Of Trustees Of The University Of Illinois Conjugates of folate anti-effector cell antibodies
ES2197265T3 (es) 1997-05-09 2004-01-01 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Conjugado que comprende un anatagonista de aacido folico y un portador.
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
AU2011289579B2 (en) 2010-08-10 2016-11-17 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
CA2946064C (en) 2014-02-21 2023-09-26 Ecole Polytechnique Federale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10309959B2 (en) 2014-12-03 2019-06-04 Life Technologies Corporation Charged reactive oligomers
EP3227264B1 (en) * 2014-12-03 2020-10-21 Life Technologies Corporation Hydrazinyl and aminooxy compounds and their methods of use
EP3638296A1 (en) 2017-06-16 2020-04-22 The University Of Chicago Compositions and methods for inducing immune tolerance
EP3790577A4 (en) 2018-05-09 2022-04-27 The University of Chicago COMPOSITIONS AND METHODS RELATED TO IMMUNTOLERANCE

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1595101A (en) * 1977-03-15 1981-08-05 Hoffmann La Roche Enzyme modifier immunoassay
FR2402664A1 (fr) * 1977-09-07 1979-04-06 Agronomique Inst Nat Rech Produits de couplage phosphorylcholine, composes amines procede d'obtention et applications
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
US4584375A (en) * 1984-08-21 1986-04-22 Rensselaer Polytechnic Institute Fluorine-containing antifolates incapable of polyglutamate formation
AU583854B2 (en) * 1984-09-13 1989-05-11 Cytogen Corporation Antibody therapeutic agent conjugates

Also Published As

Publication number Publication date
WO1987006837A1 (en) 1987-11-19
CA1330378C (en) 1994-06-21
DE3789788D1 (de) 1994-06-16
FI880059L (fi) 1988-01-07
DK5188D0 (da) 1988-01-07
JPS63503144A (ja) 1988-11-17
EP0251455B1 (en) 1994-05-11
AU7359087A (en) 1987-12-01
ATE105484T1 (de) 1994-05-15
FI880059A0 (fi) 1988-01-07
DK5188A (da) 1988-04-15
EP0251455A2 (en) 1988-01-07
JP2564586B2 (ja) 1996-12-18
FI880059A7 (fi) 1988-01-07
DE3789788T2 (de) 1994-08-18
ZA873305B (en) 1987-11-02
EP0251455A3 (en) 1990-09-05

Similar Documents

Publication Publication Date Title
CA1064826A (en) Antigen binding dimer bound to drug
CA1333442C (en) Wavelength-specific cytotoxic agents
US5314905A (en) Pyropheophorbides conjugates and their use in photodynamic therapy
US5030621A (en) Shed melanoma antigen compositions
CA2125189C (en) Pyropheophorbides and their use in photodynamic therapy
EP0253202A2 (en) Novel immunoconjugates and methods for their use in tumor therapy
Millar et al. The modification of melphalan toxicity in tumor bearing mice by s-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR2721)
EP0175617A2 (en) Antibody-therapeutic agent conjugates
CY1108597T1 (el) Συνθεσεις που περιεχουν παραγοντα συνδεσης υποδοχεα οχ-40 ή νουκλεϊνικο οξυ που κωδικοποιει αυτον και μεθοδοι για αυξηση της αντιγονου-ειδικης ανοσοαποκρισης
DE3789788D1 (de) Aminderivate von Folsäure Analogen.
TR200102411T2 (tr) Nikotin bağımlılığının önlenmesi ve tedavisi için hapten-taşıyıcı konjugatlar.
TR199701547T1 (xx) Polisakarit antijen protein e�leni�i i�eren a��.
WO1998011827A1 (en) Modulation of wound healing by photodynamic therapy
TNSN93045A1 (fr) Nouveaux composes actifs
AR008680A1 (es) Substitutos de plaquetas y metodos de conjugacion apropiados para su preparacion
KR960704543A (ko) 악성 질환의 치료를 위한 비경구투여용 부설판(Parenteral Busulfan for treatment of malignant disease)
ES2099075T3 (es) Conjugados de antraciclina con un nuevo engarce y procedimientos para su produccion.
AR016427A1 (es) CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE.
US5194384A (en) Method for preparing human meloma vaccine
US7402317B2 (en) Anti-cancer vaccine
CN104399094B (zh) 靶向硼制剂及其制备方法
AR034331A1 (es) Una molecula de conjugado inmunogenico, metodo para su preparacion, composicion farmaceutica y vacuna que lo comprenden, anticuerpo purificado y equipo de inmunoensayo de diagnostico que lo incluye
Davis et al. Modified polyvinyl alcohol‐benzoporphyrin derivative conjugates as phototoxic agents
JPS63301832A (ja) イムノグロブリン結合体
US5993829A (en) Anti-cancer vaccine

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 251455

Country of ref document: ES